Chagro-Panga

What is Chagro-Panga?

Chagro-Panga, more often called chaliponga, is a climbing vine (Diplopterys cabrerana) of the western Amazon, related to the ayahuasca vine. Its leaves are prized as a strong DMT-containing admixture and are used in place of, or alongside, chacruna in some ayahuasca traditions.

Traditional & Modern Uses

In parts of Ecuador, Colombia and Peru the leaves of chaliponga are added to Banisteriopsis caapi to make ayahuasca, valued for producing particularly vivid and long-lasting visionary effects. As with chacruna, the MAO-inhibiting beta-carbolines of the caapi vine render the leaf’s tryptamines orally active. Its use is embedded in indigenous and mestizo healing and ceremonial practice.

Phytochemistry

The leaves are dominated by the indole alkaloid N,N-DMT, present at roughly 0.17–1.75% of dry leaf — generally higher than in chacruna, which contributes to the plant’s reputation for strong, long-lasting effects ^{1Reference 1Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyana — phytochemical analysisView study →}. Classic analysis of the leaf also found traces of 5-MeO-DMT, bufotenine and the β-carboline N-methyltetrahydro-beta-carboline ^{1Reference 1Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyana — phytochemical analysisView study →}. The presence of 5-MeO-DMT, although minor, is often cited as giving its effects a somewhat distinct character. As always, alkaloid levels vary between plants.

Constituent Summary

Figures are percentages of dried leaf; DMT content is highly variable, and the accompanying tryptamines and β-carboline occur only in trace amounts. † marks the marker constituent that identifies chagro-panga as a DMT-bearing ayahuasca admixture.

Pharmacology & Research

The published science on chagro-panga is small and almost entirely indirect. No pharmacological or clinical study has ever tested Diplopterys cabrerana on its own; the species-specific literature is confined to mid-century phytochemistry establishing N,N-DMT as the dominant leaf alkaloid ^{1,2Reference 1Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyana — phytochemical analysisView study →Reference 2Der Marderosian AH et al. · 1968Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyana — phytochemical analysisView study →}, the mechanistic finding that the leaf’s tryptamines are only orally active because a co-administered β-carboline inhibits monoamine oxidase ^{3Reference 3McKenna DJ et al. · 1984In vitroMonoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca — in vitro enzyme assayView study →}, and human pharmacokinetics of DMT once it is delivered in an ayahuasca brew ^{4Reference 4Riba J et al. · 2012Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca — human pharmacokinetic studyView study →}. Everything else is inference from two better-studied levels: whole ayahuasca, in which chaliponga is one interchangeable DMT-donating leaf, and the isolated tryptamines it carries. On that borrowed evidence the strongest signal is antidepressant, resting on one small randomised controlled trial and a supportive meta-analysis for ayahuasca ^{5,8Reference 5Palhano-Fontes F et al. · 2019RCTRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial — RCTView study →Reference 8Yao Y et al. · 2024Meta-analysisEfficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysisView study →}, while the more mechanistically interesting work on DMT-driven neurogenesis remains preclinical ^{10,11Reference 10Morales-García JA et al. · 2020In vitroN,N-dimethyltryptamine regulates adult neurogenesis in vitro and in vivo — animal and cell-line studyView study →Reference 11Lima da Cruz RV et al. · 2018AnimalA single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus — in vivo animal studyView study →}. The load-bearing caveat runs through everything below: these findings were generated with chacruna-based brews or purified compounds at controlled doses, not with the leaf as it is actually used, and the whole tryptamine payload is inert without an MAOI.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up.

Indication	Support	Rests on
Antidepressant	██████░░░░ 64%	Strong ayahuasca RCT + meta-analysis, but built on chacruna brews; capped because no chaliponga-specific trial exists and the effect is attributed to DMT + MAOI, not the leaf.
Neuroplasticity & neurogenesis	█████░░░░░ 54%	Replicated rodent and organoid signal for isolated DMT/5-MeO-DMT via sigma-1/5-HT2A; no human data, and doses/routes are not how the leaf is used.
Anxiety & wellbeing	████░░░░░░ 45%	Human, but mostly secondary endpoints and acute mindfulness measures in ayahuasca users; no dedicated anxiety-disorder trial, prep-mismatched.

1. Antidepressant

The antidepressant case is the plant’s strongest, and it is entirely a case about the brew it feeds into. In the only randomised controlled trial, a single dose of ayahuasca outperformed placebo in 29 patients with treatment-resistant depression, with between-group depression-rating differences that grew over the week after dosing (MADRS Cohen’s d = 1.49 at day 7) and a 64% response rate versus 27% for placebo ^{5Reference 5Palhano-Fontes F et al. · 2019RCTRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial — RCTView study →}. This built on open-label work: six inpatients showed up to 82% reductions in depression scores across three weeks ^{6Reference 6Osório FL et al. · 2015Clinical trialAntidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report — open-label trialView study →}, and a companion single-photon emission tomography study linked the effect to increased blood flow in mood-regulating regions ^{7Reference 7Sanches RF et al. · 2016Clinical trialAntidepressant effects of a single dose of ayahuasca in patients with recurrent depression — open-label SPECT studyView study →}. A 2024 systematic review and meta-analysis placed ayahuasca’s pooled antidepressant effect at Hedges’ g = −1.34 (95% CI −1.86 to −0.82), second only to psilocybin among the psychedelics examined ^{8Reference 8Yao Y et al. · 2024Meta-analysisEfficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysisView study →}. The active tryptamine in all of these brews is N,N-DMT, exactly the alkaloid chaliponga supplies and at leaf concentrations generally higher than chacruna’s, which is why the signal plausibly transfers. What it does not do is transfer proven: the trial brews used chacruna, doses were standardised to DMT content rather than to leaf, and the antidepressant response depends on the β-carboline MAOI that makes any of the DMT orally available in the first place ^{3,4Reference 3McKenna DJ et al. · 1984In vitroMonoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca — in vitro enzyme assayView study →Reference 4Riba J et al. · 2012Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca — human pharmacokinetic studyView study →}.

Gap: No trial has used D. cabrerana; the evidence is for a standardised whole brew, and the leaf’s own dose-response, consistency, and safety margin in this indication are unknown.

2. Neuroplasticity & neurogenesis

The most mechanistically interesting work concerns what the leaf’s tryptamines do to neurons, and here the evidence is preclinical but unusually consistent. In mice, N,N-DMT activated the subgranular zone of the hippocampal dentate gyrus (a principal site of adult neurogenesis), increased the production of new neurons, and improved performance on memory tasks; the effect was abolished by a sigma-1 receptor antagonist, implicating that receptor alongside DMT’s serotonergic activity ^{10Reference 10Morales-García JA et al. · 2020In vitroN,N-dimethyltryptamine regulates adult neurogenesis in vitro and in vivo — animal and cell-line studyView study →}. The leaf’s minor constituent 5-MeO-DMT produced a parallel result: a single dose stimulated dentate-gyrus cell proliferation and neuronal survival in adult mice ^{11Reference 11Lima da Cruz RV et al. · 2018AnimalA single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus — in vivo animal studyView study →}, and in human cerebral organoids it rapidly remodelled proteins governing cytoskeletal and synaptic structure ^{12Reference 12Dakic V et al. · 2017In vitroShort-term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT — in vitro studyView study →}. Receptor-level work situates these tryptamines as agonists at 5-HT2A and, for the methoxylated compound, 5-HT1A ^{13,14Reference 13Warren AL et al. · 2024Structural pharmacology and therapeutic potential of 5-methoxytryptamines — receptor pharmacologyView study →Reference 14Riga MS et al. · 2018AnimalThe serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice — in vivo animal studyView study →}, the same pathway through which 5-HT2A activation drives ayahuasca’s measurable cortical effects in humans ^{15Reference 15Valle M et al. · 2016RCTInhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans — randomized controlled studyView study →}. Together this maps a plausible route from tryptamine to structural plasticity, but every experiment used isolated compounds, often at doses or by routes (including intracerebroventricular injection) far removed from a leaf drunk in a brew, and none measured neurogenesis in a person.

Gap: Entirely preclinical and single-compound; no evidence that whole chaliponga, or a realistically dosed brew, produces neurogenesis in humans.

3. Anxiety & wellbeing

Beyond depression, ayahuasca has shown acute effects on anxiety and psychological wellbeing, though on thinner and less direct footing. A controlled human study found that a single ayahuasca session increased mindfulness-related capacities, particularly the ability to accept experience without reacting, a construct linked to lower anxiety ^{9Reference 9Soler J et al. · 2016Clinical trialExploring the therapeutic potential of ayahuasca: acute intake increases mindfulness-related capacities — human studyView study →}. Anxiolytic and wellbeing improvements also appear as secondary outcomes within the depression trials and are folded into the 2024 meta-analysis, which reported benefits extending to anxiety symptoms ^{8Reference 8Yao Y et al. · 2024Meta-analysisEfficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysisView study →}. The mechanism is presumed to overlap with the antidepressant one: acute 5-HT2A-driven changes in self-referential processing ^{15Reference 15Valle M et al. · 2016RCTInhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans — randomized controlled studyView study →} followed by a sustained “afterglow.” The evidence stops short of a dedicated trial in an anxiety disorder, rests substantially on secondary endpoints and acute-state measures, and (as everywhere here) describes the brew rather than the leaf.

Gap: No primary anxiety-disorder trial; signal is secondary-outcome and acute-state, brew-level, and not specific to chaliponga.

Mechanisms

Mechanism	Drives	Key compounds
5-HT2A receptor agonism	antidepressant, anxiety/wellbeing, acute visionary effects	N,N-DMT, 5-MeO-DMT
Sigma-1 receptor activation	neuroplasticity, neurogenesis	N,N-DMT
5-HT1A receptor agonism	cortico-thalamic modulation (5-MeO-selective)	5-MeO-DMT, bufotenine
Monoamine oxidase inhibition (by co-administered β-carbolines)	enabling oral bioavailability of all leaf tryptamines	N-methyltetrahydro-β-carboline; harmala alkaloids from the caapi vine

Clinical trials

No registered clinical trial has studied Diplopterys cabrerana itself; the ~13 ayahuasca and ~50 DMT trials on ClinicalTrials.gov test the whole brew or the isolated compound, so the numbers below count the ayahuasca programme the plant feeds into, not chaliponga.

Completed	Planned	Terminated	Preclinical
~6 (ayahuasca)	~4 (recruiting/not-yet)	0	~10+

Last checked: July 2026.

Safety

Chaliponga is a potent DMT-bearing leaf and carries the full risk profile of the ayahuasca brews it is used in. Its tryptamines are orally inactive alone and become active only when combined with a monoamine-oxidase-inhibiting β-carboline; that MAO inhibition is itself the central hazard, producing serious sensitivity to tyramine-containing foods and to a wide range of medications, with potential for hypertensive reactions and for serotonin toxicity when combined with SSRIs, SNRIs, MAOIs, or other serotonergic drugs ^{3,4,16Reference 3McKenna DJ et al. · 1984In vitroMonoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca — in vitro enzyme assayView study →Reference 4Riba J et al. · 2012Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca — human pharmacokinetic studyView study →Reference 16Callaway JC · 1998ReviewAyahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions — case-based pharmacology reviewView study →}. Case-based pharmacology specifically warns that ayahuasca-type preparations taken with serotonin-reuptake inhibitors can precipitate a serotonin syndrome with potentially grave outcome ^{16Reference 16Callaway JC · 1998ReviewAyahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions — case-based pharmacology reviewView study →}. The leaf also supplies minor amounts of 5-MeO-DMT and bufotenine, more powerful and less predictable tryptamines that add to the intensity of effect ^{1,13Reference 1Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyana — phytochemical analysisView study →Reference 13Warren AL et al. · 2024Structural pharmacology and therapeutic potential of 5-methoxytryptamines — receptor pharmacologyView study →}. Broader reviews find that acute and long-term ayahuasca use is not markedly toxic in physically healthy, screened adults, but caution that cardiovascular, psychiatric, and drug-interaction risks are real and that DMT is a controlled substance in many jurisdictions ^{17,18Reference 17dos Santos RG · 2013ReviewSafety and side effects of ayahuasca in humans — an overview focusing on developmental toxicology — reviewView study →Reference 18Hamill J et al. · 2019ReviewAyahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness — reviewView study →}. This is a plant for experienced, well-prepared ceremonial contexts with medical and pharmacological screening — never casual use, and never alongside serotonergic medication.

Scope note: interactions were assessed for the MAOI mechanism the leaf is used within — tyramine-food and serotonergic-drug interactions are well documented for ayahuasca-type preparations and apply directly ^{3,4,16Reference 3McKenna DJ et al. · 1984In vitroMonoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca — in vitro enzyme assayView study →Reference 4Riba J et al. · 2012Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca — human pharmacokinetic studyView study →Reference 16Callaway JC · 1998ReviewAyahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions — case-based pharmacology reviewView study →}. Pregnancy and lactation were not studied for this plant; the ayahuasca developmental data are limited and preclinical/observational only ^{17Reference 17dos Santos RG · 2013ReviewSafety and side effects of ayahuasca in humans — an overview focusing on developmental toxicology — reviewView study →}. Absence of reports is not evidence of safety.

Pregnancy & lactation

Verdict: Avoid. Pregnancy and lactation safety for chaliponga specifically has not been researched. The available reviews of ayahuasca focus on developmental toxicology and report that controlled human data in pregnancy are lacking; animal developmental studies raise possible concerns and cannot be dismissed ^{17Reference 17dos Santos RG · 2013ReviewSafety and side effects of ayahuasca in humans — an overview focusing on developmental toxicology — reviewView study →}. Given a psychoactive, MAO-dependent, serotonergically active preparation with no human pregnancy safety data, avoidance during pregnancy and breastfeeding is the only defensible position — this is an “avoid because unstudied and high-risk,” not an inference of safety from silence.

Dosage

Note: chaliponga is not used as a standalone therapeutic herb; it is a ceremonial ayahuasca admixture, active only with an MAOI, and a controlled substance in many jurisdictions. The tables below are descriptive/ethnographic, drawn from the research and pharmacology literature — not a preparation guide or a recommendation.

Research doses (one row per indication that reported one — cited with its [n]):

Indication	Preparation	Dose	Est. dried-herb equivalent	Source
Antidepressant	Standardised whole ayahuasca (chacruna-based, DMT-quantified)	Single dose ~0.36 mg DMT/kg body weight	— (brew standardised to DMT, not to chaliponga leaf; no valid leaf back-conversion)	5Reference 5Palhano-Fontes F et al. · 2019RCTRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial — RCTView study →
Antidepressant	Whole ayahuasca (open-label)	Single ceremonial dose	—	6,7Reference 6Osório FL et al. · 2015Clinical trialAntidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report — open-label trialView study →Reference 7Sanches RF et al. · 2016Clinical trialAntidepressant effects of a single dose of ayahuasca in patients with recurrent depression — open-label SPECT studyView study →
Neuroplasticity	Isolated DMT / 5-MeO-DMT, animal (incl. ICV)	Not human-applicable	— (non-oral routes; not convertible to leaf)	10,11Reference 10Morales-García JA et al. · 2020In vitroN,N-dimethyltryptamine regulates adult neurogenesis in vitro and in vivo — animal and cell-line studyView study →Reference 11Lima da Cruz RV et al. · 2018AnimalA single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus — in vivo animal studyView study →

Est. dried-herb equivalent is deliberately left ”—”. The trials dosed by DMT content of a chacruna brew, not by chaliponga leaf mass; and leaf DMT ranges roughly 0.17–1.75% ^{1Reference 1Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyana — phytochemical analysisView study →}, a ~10× spread that makes any single back-conversion misleading. If one were forced: at ~1% leaf DMT, a ~25 mg DMT dose ≈ ~2.5 g dried leaf — order-of-magnitude only, not a dosing instruction.

Traditional Dosage

Traditionally, chaliponga is never taken alone or by a standardised amount: the leaves are boiled together with the MAOI vine into an ayahuasca decoction, with quantities set by the practitioner rather than by weight.

System	Preparation	Dose
Amazonian (indigenous/mestizo) ceremonial	Leaves boiled with Banisteriopsis caapi into an ayahuasca decoction; a handful of leaves per brew, quantities set by the practitioner	Not standardised — determined by tradition/practitioner; always with the MAOI vine

References

1. Agurell S, Holmstedt B, Lindgren JE, Schultes RE. (1968). Alkaloid content of Banisteriopsis rusbyana — phytochemical analysis. Biochem Pharmacol. https://pubmed.ncbi.nlm.nih.gov/5698439/
2. Der Marderosian AH, Pinkley HV, Dobbins MF. (1968). Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyana — phytochemical analysis. Am J Pharm Sci Support Public Health. https://pubmed.ncbi.nlm.nih.gov/5698438/
3. McKenna DJ, Towers GHN, Abbott F. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca — in vitro enzyme assay. J Ethnopharmacol. https://pubmed.ncbi.nlm.nih.gov/6587171/
4. Riba J, McIlhenny EH, Valle M, et al. (2012). Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca — human pharmacokinetic study. Drug Test Anal. https://pubmed.ncbi.nlm.nih.gov/22514127/
5. Palhano-Fontes F, Barreto D, Onias H, et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial — RCT. Psychol Med. https://pubmed.ncbi.nlm.nih.gov/29903051/
6. Osório FL, Sanches RF, Macedo LR, et al. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report — open-label trial. Braz J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/25806551/
7. Sanches RF, de Lima Osório F, dos Santos RG, et al. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression — open-label SPECT study. J Clin Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/26650973/
8. Yao Y, Guo D, Lu TS, et al. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis. Psychiatry Res. https://pubmed.ncbi.nlm.nih.gov/38574699/
9. Soler J, Elices M, Franquesa A, et al. (2016). Exploring the therapeutic potential of ayahuasca: acute intake increases mindfulness-related capacities — human study. Psychopharmacology (Berl). https://pubmed.ncbi.nlm.nih.gov/26612618/
10. Morales-García JA, Calleja-Conde J, López-Moreno JA, et al. (2020). N,N-dimethyltryptamine regulates adult neurogenesis in vitro and in vivo — animal and cell-line study. Transl Psychiatry. https://pubmed.ncbi.nlm.nih.gov/32989216/
11. Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN. (2018). A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus — in vivo animal study. Front Mol Neurosci. https://pubmed.ncbi.nlm.nih.gov/30233313/
12. Dakic V, Minardi Nascimento J, Costa Sartore R, et al. (2017). Short-term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT — in vitro study. Sci Rep. https://pubmed.ncbi.nlm.nih.gov/28993683/
13. Warren AL, Lankri D, Cunningham MJ, et al. (2024). Structural pharmacology and therapeutic potential of 5-methoxytryptamines — receptor pharmacology. Nature. https://pubmed.ncbi.nlm.nih.gov/38720072/
14. Riga MS, Lladó-Pelfort L, Artigas F, Celada P. (2018). The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice — in vivo animal study. Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/29221792/
15. Valle M, Maqueda AE, Rabella M, et al. (2016). Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans — randomized controlled study. Eur Neuropsychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27039035/
16. Callaway JC, Grob CS. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions — case-based pharmacology review. J Psychoactive Drugs. https://pubmed.ncbi.nlm.nih.gov/9924842/
17. dos Santos RG. (2013). Safety and side effects of ayahuasca in humans — an overview focusing on developmental toxicology — review. J Psychoactive Drugs. https://pubmed.ncbi.nlm.nih.gov/23662333/
18. Hamill J, Hallak J, Dursun SM, Baker G. (2019). Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness — review. Curr Neuropharmacol. https://pubmed.ncbi.nlm.nih.gov/29366418/
19. Goldin D, Salani D. (2021). Ayahuasca: what healthcare providers need to know — clinical review. J Addict Nurs. https://pubmed.ncbi.nlm.nih.gov/34060770/